Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | PREP | P48147 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3134513 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL5702006 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| Hydrochloric Acid SCHEMBL7246637 | 0.98 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL29553 | 0.91 | PREP (0.67) | SMN1; SMN2PREPCTRB1NPSR1ALDH1A1 | |
| SCHEMBL29658848 | 0.91 | PREP (0.67) | SMN1; SMN2PREPCTRB1NPSR1ALDH1A1 | |
| SCHEMBL475715 | 0.91 | PREP (0.67) | SMN1; SMN2PREPCTRB1NPSR1ALDH1A1 | |
| SCHEMBL205223 | 0.91 | PREP (0.67) | SMN1; SMN2PREPCTRB1NPSR1ALDH1A1 | |
| SCHEMBL82714 | 0.90 | PREP (0.62) | SMN1; SMN2NPC1RAB9APREPCTRB1 | |
| SCHEMBL630208 | 0.90 | PREP (0.62) | SMN1; SMN2NPC1RAB9APREPCTRB1 | |
| SCHEMBL630241 | 0.90 | PREP (0.62) | SMN1; SMN2NPC1RAB9APREPCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113631560-B | Azetidine benzodiazepine dimers and conjugates comprising the same for the treatment of cancer | 麦迪穆有限责任公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. | 2024-04-25 | — | — | US | disclosed |
| EP-3938372-B1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LTD (GB) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-3938372-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MedImmune Limited (GB) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020187721-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LIMITED (GB) | 2020-09-24 | — | — | WO | disclosed |
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084968-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3334728-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| US-5578612-A | Indole derivatives | PFIZER INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5559129-A | SEROTONIN (5HT1) ANTAGONIST FOR TREATMENT OF DEPRESSION, ANXIETY, EATING DISORDERS, OBESITY, DRUG ABUSE, HEADACHES, AND PAIN | PFIZER INC (US) | 1996-09-24 | — | — | US | disclosed |
| US-5559246-A | PROCESS OF DEHYDROHALOGENATION FOR CYCLIZATION TO PRODUCE PSYCHOTHERAPEUTIC AGENTS AND ANTISEROTONIN ANTAGONIST | PFIZER INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5545644-A | SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS | PFIZER INC. (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0503044-B1 | PEPTIDE COMPOUNDS OF LAEVOROTATORY AMINO ACIDS AND RING MOLECULES, AND THERAPEUTICAL APPLICATIONS THEREOF | POLIFARMA SPA (IT) | 1996-06-12 | — | — | EP | disclosed |
| US-5504071-A | HYPOTENSIVE AGENTS | POLIFARMA S.P.A. (IT) | 1996-04-02 | — | — | US | disclosed |
| EP-0592438-A1 | INDOLE DERIVATIVES. | PFIZER (US) | 1994-04-20 | — | — | EP | disclosed |
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | disclosed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | disclosed |
| US-4043993-A | New pentapeptides and methods for their production | PARKE, DAVIS & COMPANY (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | SMN1; SMN2 2280/4885NPC1 2594/4885RAB9A 3333/4885 |
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | DLD, GCDH, DLAT | SMN1; SMN2 4854/4885NPC1 1289/4885RAB9A 2600/4885 |
| US-20190084968-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | SMN1; SMN2 2280/4885NPC1 2594/4885RAB9A 3333/4885 |
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | METAP2, FAP, FOLH1 | SMN1; SMN2 2280/4885NPC1 2594/4885RAB9A 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.